loading page

Active Surveillance for Patients with Micro Papillary Thyroid Cancer in UK
  • +3
  • Pavithran Maniam,
  • Noah Harding,
  • Lucy Li,
  • Richard Adamson,
  • Ashley Hay,
  • Iain Nixon
Pavithran Maniam
Royal Infirmary of Edinburgh

Corresponding Author:[email protected]

Author Profile
Noah Harding
Department of Otorhinolaryngology Head and Neck Surgery, NHS Lothian, Edinburgh, UK
Author Profile
Lucy Li
Queen Elizabeth University Hospital
Author Profile
Richard Adamson
Department of Otorhinolaryngology Head and Neck Surgery, NHS Lothian, Edinburgh, UK
Author Profile
Ashley Hay
NHS Lothian
Author Profile
Iain Nixon
NHS Lothian
Author Profile

Abstract

Background The incidence of thyroid cancer is increasing globally due to the increase in detection of subclinical, low volume papillary thyroid microcarcinomas (PTMC) (<1cm). Several international groups have recommended an active surveillance approach for this low-risk disease. In contrast to many other countries, the UK’s approach to thyroid nodules is to avoid detection of incidental lesions where appropriate. Objective This study aims to establish the proportion of patients with thyroid cancer in the UK that would benefit from active surveillance. Design, participants, and outcome measures: Individuals with PTMC in NHS Lothian from 2009-2020 were reviewed from a local thyroid cancer database. The mode of detection of PTMC and proportion of patients who might benefit from active surveillance were established. Results From 651 individuals with differentiated thyroid cancer managed over 12-year period, 185 individuals with PTMC were identified (28.4%). The majority of PTMC 151/185 (81.6%) were either diagnosed post-operatively following thyroidectomy for benign disease or with nodal disease. Only 24 individuals with PTMC were identified following palpable thyroid nodule, incidental finding on imaging and surveillance screening. Therefore, when the indication for surgery was considered, only 24/651 (3.7%) patients were identified pre-operatively and would therefore be realistic candidates for active surveillance. Conclusion Less than 4% of patients with thyroid cancer in the UK would be appropriate for active surveillance. Rather than developing programs to deal with this minority of patients, focus should be maintained on minimizing detection of these low-risk cases.
28 Dec 2021Submitted to Clinical Otolaryngology
04 Jan 2022Submission Checks Completed
04 Jan 2022Assigned to Editor
07 Feb 2022Reviewer(s) Assigned
01 Jul 2022Review(s) Completed, Editorial Evaluation Pending
03 Jul 2022Editorial Decision: Revise Minor
27 Jul 20221st Revision Received
17 Aug 2022Submission Checks Completed
17 Aug 2022Assigned to Editor
19 Aug 2022Reviewer(s) Assigned
03 Sep 2022Review(s) Completed, Editorial Evaluation Pending
17 Sep 2022Editorial Decision: Accept